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Gitelman syndrome is one of the few inherited causes of metabolic alkalosis due to salt losing tubulopathy. It is caused by tubular
defects at the level of distal convoluted tubules, mimicking a thiazide-like tumor. It usually presents in late childhood or in teenage
as nonspeciﬁc weakness, fatigability, polyuria, and polydipsia but very rarely with seizures. It is classically associated with
hypokalemia, hypomagnesemia, hypocalciuria, hyperreninemia, and hyperaldosteronism. However, less frequently, it can present
with normal magnesium levels. It is even rarer to ﬁnd normomagnesemic patients of GS who develop seizures as the main
complication since hypomagnesemia is considered the principal etiology of abnormal foci of seizure-related brain activity in GS
cases. Interestingly, patients with GS are oftentimes diagnosed during pregnancy when the classic electrolyte pattern consistent
with GS is noticed. Our case presents GS with normal serum magnesium in a patient, with seizures being the main clinical
presentation.We also did a comprehensive literature review of 122 reported cases to show the prevalence of normal magnesium in
GS cases and an overview of clinical and biochemical variability in GS. We suggest that further studies and in-depth analysis are
required to understand the pathophysiology of seizures in GS patients with both normal and low magnesium levels.
1. Materials and Methods
Two diﬀerent databases (PubMed and Scopus) were
searched for all case reports and review articles previously
published on GS syndrome.Moreover, after taking informed
consent from our patient, we included data from the elec-
tronic medical record system to use this information for
publication purposes.
2. Case Presentation
A 22-year-old female was brought to the hospital with the
complaint of vomiting, generalized weakness, and two ep-
isodes of witnessed generalized tonic-clonic seizures
24 hours prior to the time of admission. She had about 5
episodes of nonbloody nonbilious vomiting. She was non-
verbal at baseline but was reported to be more lethargic than
usual and had a poor oral intake for the last 2 days and
appeared to be in pain. Review of the system was negative for
any previous episodes of seizures in the past, fever, diarrhea,
abdominal pain, history of diuretic or laxative abuse, any
periorbital puﬃness, and extremities swelling. She was given
lorazepam followed by successful resolution of seizures.
On physical examination, she was having borderline low
blood pressure close to her baseline (105/56) with HR of 80,
RR 18, O2 sat. 100% on room air. Systemic examination
was otherwise unremarkable without any overt signs of
dehydration.
EKG showed U waves and nonspeciﬁc T wave changes.
Pertinent labs showed serum blood urea nitrogen (BUN)
and creatinine (Cr) of 16 and 0.77, respectively. Serum
electrolytes showed serum sodium (Na) of 150mEq/L, se-
rum potassium (K) of 1.4mEq/L, serummagnesium (Mg) of
2.8mg/dL, and serum bicarbonate (HCO3) of 35mEq/L.
Urine electrolytes included urine K 22mEq/L, urine Na
121mEq/L, and urine Cl 146mEq/L. Her transtubular
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Table 1: Summary of the literature review.
Demographics Total (%) Associations Total (%)
Age, mean 31 Pregnancy 17 (14)
Range 0.3–80 years Calcium pyrophosphate deposition disease (CPPD) 7 (5.7)
Males 45 (36) Sjogren syndrome 5 (4)
Females 77 (63) Chondrocalcinosis 4 (3.3)
Presentation +yrotoxicosis hypokalemic periodic paralysis(THPP) 2 (1.6)
Weakness 52 (43) Empty sella syndrome 2 (1.6)
Cramps 23 (19) Type 2 diabetes 2 (1.6)
Carpopedal spasms 11 (9) Primary aldosteronism 2 (1.6)
Nausea, vomiting 7 (6) Type 1 diabetes 1 (0.8)
Nocturia 6 (5) Pemphigus vegetans 1 (0.8)
Paralysis 5 (4) Mitochondrial encephalopathy 1 (0.8)
Numbness 5 (4) Varicose veins 1 (0.8)
Joint pain, arthritis 4 (3) each Fanconi syndrome 1 (0.8)
Muscle pain 3 (2) Autosomal dominant familial neurohypophysealdiabetes insipidus 1 (0.8)
Polydipsia 3 (2) Syndrome of inappropriate ADH secretion 1 (0.8)
Sicca symptoms 3 (2) Familial Mediterranean fever 1 (0.8)
Hypokalemic paralysis 2 (1.6) Parathyroid adenoma 1 (0.8)
Syncope 2 (1.6) Pancreatic cancer 1 (0.8)
Salt craving 2 (1.6) Hashimoto thyroiditis 1 (0.8)
+irst, palpitations, frequent micturition,
somnolence 1 (0.8) each Scleroderma 1 (0.8)
Nausea, vomiting 7 (6) Crowded lens syndrome 1 (0.8)
Paralysis 5 (4) Transient hypophosphatemia of infancy 1 (0.8)
Visual abnormalities 4 (3) Pseudotumor cerebri 1 (0.8)
Failure to thrive 4 (3) Gout 1 (0.8)
Loss of appetite 4 (3) Graves disease 1 (0.8)
Respiratory distress 3 (2) Serum Electrolytes Total (%)
Arthralgias 2 (1.6) Sodium
Headache 2 (1.6) Normal range (135–145mEq/L) 46 (38)
Diarrhea 2 (1.6) Low 15 (12)
Raynaud’s phenomenon 2 (1.6) Potassium
Incontinence 1 (0.8) Normal range (3.5–5mEq/L) 14 (11)
Insomnia 1 (0.8) Lower limit (2.5–3mEq/L) 57 (47)
Tinnitus 1 (0.8) Low (<2.5mEq/L) 41 (34%)
Perspiration 1 (0.8) Calcium
Constipation 1 (0.8) Normal range (2.2–2.7mmol/L) 42 (34)
Complications Low 13 (11)
Metabolic alkalosis 7 (5.7) High 2 (1.6)
Hypokalemic paralysis 6 (4.9) Magnesium
Hypokalemia 5 (4) Normal range (0.70–1.0mmol/L) 19 (16)
Prolonged QT intervals 5 (4) Low 69 (57)
Pseudogout 4 (3.3) High 6 (5)
Rhabdomyolysis 4 (3.3) Urine analysis
ST depression 2 (1.6) Sodium
T wave changes on EKG 2 (1.6) mmol/24h
Gestational diabetes mellitus 2 (1.6) Normal (40–220mmol/24 h) 17 (14)
Focal segmental glomerulosclerosis 2 (1.6) High 14 (11)
Prominent U waves 2 (1.6) Spot (mmol/L)
Tubulointerstitial nephritis 2 (1.6) Normal (<20mmol/L) 1 (0.8)
Brain calciﬁcation 1 (0.8) High 3 (2.5)
Diabetic ketoacidosis 1 (0.8) Potassium
Left ventricular dysfunction 1 (0.8) mmol/24h
Prolonged PR interval 1 (0.8) Normal (25–125mmol/24 h) 30 (25)
Ventricular ﬁbrillation 1 (0.8) High 8 (6.5)
MPGN 1 (0.8) Low 2 (1.6)
Focal seizures 1 (0.8) Spot (mmol/L)
Iron deﬁciency anemia 1 (0.8) Normal (20–40mmol/L) 3 (2.5)
Pericardial eﬀusion 1 (0.8) High 3 (2.5)
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potassium gradient (TTKG) was 6.82. Complete blood count
and liver function panel were within normal limits. Plasma
renin activity (PRA) was 0.33 ng/ml/hr, serum aldosterone/
K ratio of 1/1.4, and aldosterone/plasma renin ratio of 3.
Diﬀerential included primary hyperaldosteronism, vomit-
ing, and Bartter/Gitelman syndrome.
EEG showed abnormal epileptiform activity in the brain
consistent with seizure. Low normal BP, high urine Cl with
urine Ca, and history negative for laxative/diuretic intake
made GS the more likely diﬀerential. Later on, biallelic
identiﬁcation of inactivating SLC12A3 mutation conﬁrmed
the diagnosis of GS.
Patient’s condition improved with aggressive K re-
plenishment and antiepileptics in the medical ICU. She was
later discharged in a medically stable condition and advised
to follow-up with nephrologist and neurologist as an
outpatient.
3. Literature Search
+e available literature was systematically searched by
three authors independently to retrieve all available ma-
terial on variable clinical and metabolic presentations in
Gitelman syndrome. +ere was no language ﬁlter placed,
and articles were collected from their inception till May
2018, using the MEDLINE, Cochrane, Embase, and Scopus
databases. Diﬀerent MeSH terminologies such as “Gitel-
man,” “Gitelman syndrome,” “Gitelman disease,” and
“GS” were combined using the Boolean operators “AND”
and “OR” with the terms “hypomagnesemia,” “low mag-
nesium,” “serum magnesium,” “plasma magnesium,” and
“magnesium levels.” Another author collected few articles
through manual search using the reference list of all re-
trieved publications through the aforementioned search
strategy.
4. Results and Statistical Analysis
4.1. Literature Retrieval and the Results. After a thorough
computer literature search, careful veriﬁcation of references,
and screening based upon the titles and abstracts, 122 cases
of GS patients from 100 articles were identiﬁed for selection
[1–100]. It was ensured that repetitive cases in these articles
were excluded. Out of these 100 articles, data were also
extracted from articles published in languages other than
English.
Table 1: Continued.
Demographics Total (%) Associations Total (%)
Neuropsychological symptoms 1 (0.8) Calcium
Sclerochoroidal calciﬁcations 1 (0.8) mmol/24h
Renal tubular acidosis 1 (0.8) Normal (15–20mmol/24 h) 2 (1.6)
High 3 (2.5)
Diagnosis Low 58 (48)
Based on electrolyte abnormality 68 (56) Spot (mmol/L)
Genetic mutations Normal (20–40mmol/L)
SLC12A3 gene mutations 46 (38) High
NCCT gene 3 (2.5) Magnesium
TSC gene 3 (2.5) mmol/24h
Screening 2 (1.6) Normal (3–5mmol/24 h) 5 (4)
CLCNKB gene 1 (0.8) High 13 (11)
Low 7 (6)
Management Spot (mmol/L)
Electrolyte replacement (Mg, K supplements) 92 (75) Normal (8–152mmol/L) 1 (0.8)
Spironolactone 32 (26) High N/A
Pain killers 13 (11) Low 1 (0.8)
Angiotensin receptor blocker 7 (5.7) Chloride (140–250mmol/24 h)
Amiloride 7 (5.7) mmol/24 h
Steroids 5 (4) Normal(140–250mmol/24 h) 2 (1.6)
Eplerenone 3 (2.5) High 3 (2.5)
Colchicine (for gout) 2 (1.6) Low 3 (2.5)
Desmopressin 2 (1.6) mmol/L
Growth hormone (for empty sella syndrome) 2 (1.6) Normal (98–107mmol/L)
Febuxostat (for gout) 1 (0.8) Low 6 (4.9)
Cyclophosphamide 1 (0.8) High 4 (3.3)
Triamterene 1 (0.8) 24 hr urinary protein
Phenytoin 1 (0.8) Normal (<80mg/24 h) 1 (0.8)
Amiodarone (for ventricular ﬁbrillation) 1 (0.8) Low
Metoclopramide 1 (0.8) High 7 (6)
Antithyroid drugs 1 (0.8) Calcium creatinine ratio
Outcome Normal (<0.14)
Recovery 86 (70) High
Low
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4.2. Patients Description. +ere were a total of 122 patients
including 45% (n � 55) males and 65% (n � 77) females. +e
age of female patients ranged from 4.8months to 79 years
(mean age 28.5 years), whereas for males, it ranged from
7months to 80 years (mean age of 27.8 years). +e de-
scription of patients included in this study is listed in Table 1.
4.3. Spectrum of Clinical Presentation and Associations.
Clinical presentation of Gitelman syndrome was found to be
highly variable in the reported patient population. About
30% (n � 36/122) of the patients, including 14%
(n � 17/122) pregnant patients, were having nonspeciﬁc
muscle cramps, weakness, fatigability, and anorexia, as the
main presentation. +ese were likely due in part to hypo-
kalemia and hypomagnesemia. About 12% (n � 15/122) of
the patients had extremities weakness out of which 7%
(n � 9/122) presented with bilateral lower limb weakness/
paralysis and the rest of them had quadriplegia as initial
presentation. Interestingly, 10.6% (n � 12/122) of patients
had perioral numbness and symptoms related to tetany/
carpopedal spasm as ﬁrst signs of Gitelman. About 6% of
patients had polydipsia, polyuria/enuresis, and salt craving
as presenting complaint; however, almost half of the total
reported patients had some degree of polydipsia and
polyuria in addition to main presenting clinical symptoms.
Seven percent (n � 9/122) of patients were completely
asymptomatic and were diagnosed with routine lab work,
either during routine clinical visits or perioperatively. Only
5.7% of patients (n � 7/122) had GI-related issues such as
anorexia, vomiting, constipation, abdominal pain, and
weight loss as the main complaint. About 7 cases had no
mention of the presenting complaints. Rest of the patients
had their own unique features as seen in Table 1. Our patient
had a unique presentation of generalized tonic-clonic seizure
despite normal serum Mg levels, which has not been pre-
viously reported in the literature. GS was found to be most
commonly associated with pseudogout and CPPD crystal
deposition in about 10% of patients. Other associations
included but not limited to Sjogren’s syndrome in 4%,
chondrocalcinosis in 3%, and diabetes mellitus (both type 1
and type 2) and primary hyperaldosteronism in about 2%
each. A less common association is seen with empty sella
syndrome in 2 patients. Seizure disorder as a possible as-
sociation with GS was previously reported in only one case
by Beltagi et al., most likely due to hypomagnesemia [15].
Our patient, however, was unique with no prior history of
epilepsy and had a seizure as the very ﬁrst presentation with
normal magnesium levels.
4.4. Complications Related to Gitelman Syndrome.
Complications related to renal, cardiac, and endocrine
systems have frequently been reported in the previous cases.
Cardiac manifestations ranged from electrolytes related,
asymptomatic ECG changes including prolonged Qtc,
nonspeciﬁc T and U waves to pericardial eﬀusion, and
ventricular ﬁbrillation. Reported renal pathologies included
glomerulonephritides such as MPGN, FSGS, membranous
nephropathy, and also cases of tubulointerstitial nephritis
and renal tubular acidosis (RTA). +yrotoxic periodic pa-
ralysis and hypokalemic periodic paralysis were also seen in
a few cases. However, it must be noted that it is rare for two
diﬀerent renal entities to occur at the same time, and several
of the studies did not conﬁrm the diagnosis of GS by
identifying the inactivation gene mutation leaving open the
possibility that underlying pathology may not have been
actually Gitelman’s. Long-term follow-up is usually required
to observe for these complications; our patient, however, had
no further follow-up in our hospital and was referred to the
neurologist care.
4.5. Diagnosis and Management with Outcomes. Except for
one case (n � 1/122), where there is no mention of the
diagnostic method, genetic testing was utilized in 42%
(n � 52/122) cases, to deﬁnitively diagnose GS. +e speciﬁc
mutations to help make the diagnosis can be seen in Table 1.
Almost 56% of patients (n � 68/122) were diagnosed based
on the presenting electrolytes abnormalities including serum
and urine Na, K, Mg, and Ca used adjunctively with PAR
concentration. Although the supportive testing with elec-
trolytes and supplementary tests were highly suggestive of
GS in these 68 cases, genetic tests were not done for various
reasons. +ese included lack of resources, nonavailability of
genetic test, and loss of follow-up by the patients to be the
major ones.
Of note is the serum Mg level in the reported cases.
Considering the normal range to be between 0.7 and
1mmol/L (1.5–2mEq/L; 1.7–2.4mg/dL), 55% (n � 66/122)
patients had hypomagnesemia, i.e., <0.7mmol/L, whereas
20% (n � 25/122) had levels 0.7mmol/L and above. In 31
cases, serum magnesium levels were not reported. +ese
levels were important as the clinical severity of presentation
was reﬂected by the degree of hypomagnesemia.
Electrolytes replacement, NSAIDs, and potassium-
sparing diuretics with and without ACE In/ARB’s were
the mainstay of treatment in almost all of the cases. Out-
comes and prognosis were remarkable, and patients fully
recovered from their acute presenting symptoms with ex-
ception of a few cases. +ese few cases reported persistent
electrolytes abnormalities such as hypokalemia, metabolic
alkalosis, hypomagnesemia, occasional paralysis and neu-
rological symptoms, and treatment-related complications
(indomethacin-related GI upset and bleeding). Recovery in
the other cases is being deﬁned as a sustained increase in
electrolytes with magnesium >2, potassium >4, and sig-
niﬁcant improvement in the symptoms. Around 22%
(n � 28/122) cases did not comment on the outcomes.
5. Discussion
However, GS can also present with normal serum magne-
sium levels, and in one case, it has been reported to be in
around 20–40% of GS cases [101]. From our review of
around 122 cases, 20% (n � 25/122) patients had serum
magnesium levels >0.7mmol/L. Both the groups of GS
patients with normal and low magnesium levels largely stay
asymptomatic and present later in life. Most present in
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teenage or adulthood with nonspeciﬁc generalized weakness
or muscle cramps/fatigability, polyuria, and polydipsia
[103]. However, seizure disorder has very rarely been re-
ported as one of the main presenting complaints. Hypo-
magnesemia and metabolic alkalosis have been proposed as
the pathophysiological basis of these rarely reported seizure
disorders. Our case reports are unique in this sense that the
patient of GS presented with seizure despite having normal
serum magnesium levels. In our literature review, only one
patient who was reported by Beltagi et al. [15] presented with
somnolence and alteredmental status and had a focal seizure
as a complication. Even in that case, hypomagnesemia can be
considered as the cause of epileptiform activity on EEG.+is
observation prompts us to consider causes other than hy-
pomagnesemia as a culprit of seizure disorder, whenever
evaluating the patient with GS. +e ﬁnal diagnosis of GS is
based on the triad of clinical symptoms, biochemical ab-
normalities, and genetic testing [103]. Genetic testing is
recommended for all patients, and the diagnosis is con-
ﬁrmed with the biallelic identiﬁcation of inactivating
SLC12A3 mutations [104]. We emphasize after this litera-
ture review that contrary to common clinical practice,
overall clinical picture with more emphasis on genetic
testing is a better strategy to clinch the diagnosis, and the
diagnosis of GS can still be made even with normal serum
magnesium levels.
5.1. Treatment. Most patients with GS remain untreated.
+e observation that chondrocalcinosis is due to magnesium
deﬁciency argues clearly in favor of magnesium supple-
mentation [15]. Most asymptomatic patients with GS remain
untreated and undergo ambulatory monitoring, once a year,
generally by nephrologists. Lifelong supplementation of
magnesium and potassium is mandatory [105]. Cardiac
workup should be performed to screen for risk factors of
cardiac arrhythmias. All GS patients are encouraged to
maintain a high-sodium diet. In general, the long-term
prognosis of GS is excellent. Health education with annual
regular nephrologist follow-up to evaluate for any developing
complications seems to be a reasonable approach. As men-
tioned in the abstract, GS can be ﬁrst identiﬁed during
pregnancy when classic electrolyte abnormalities are noticed
on the lab work [106]. Successful pregnancy is possible in
majority of the patients; however, miscarriages have also been
reported in the literature, which alludes to regular nephrol-
ogist follow-up during pregnancy.
6. Conclusion
(i) GS with variable biochemical presentation,
i.e., normal serum magnesium level is a rare but
potentially possible ﬁnding seen in various clinical
settings
(ii) Although exceedingly rare, seizure disorder can be
the main clinical presentation of GS
(iii) Causes other than low magnesium levels should be
sought for the explanation of seizure disorder in
GS
(iv) Further studies are recommended to better un-
derstand the pathophysiology of abnormal epilep-
tiform activity in GS
(v) Successful pregnancy is possible in majority of the
patients; however, miscarriages have also been re-
ported in the literature, which alludes to regular
nephrologist follow-up in the pregnant GS patient
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